Prof. Dr. SALİH SAYGIN EKER

Yayın Ağı

Makaleler 36

1. Exploring the Personality Characteristics of Rhinoplasty Patients: Perfectionism, Rumination, and Self-Compassion

Mete U., Demir U. L., Güllülü R. A., Eker S. S., Duman F., Altun N.

AESTHETIC PLASTIC SURGERY , cilt.48, sa.24, ss.5299-5305, 2024 (SCI-Expanded)

2. Antipsychotic-Treated Schizophrenia Patients Develop Inflammatory and Oxidative Responses Independently From Obesity: However, Metabolic Disturbances Arise From Schizophrenia-Related Obesity

Emre S., Asli S., Sener M., EKER S. S., Esma S.

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL , cilt.39, sa.6, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma

3. Evaluation of the effect of the COVID-19 pandemic on the depression, anxiety and stress levels of anesthesiology and reanimation doctors, and their work and social lives

SOYLU N. B., MOGOL E. B., EKER S. S., AKESEN S., SOYLU H. S.

Kastamonu Medical Journal (KASMEJ) , cilt.4, sa.2, ss.39-44, 2024 (Hakemli Dergi)

4. Successful ECT treatment of a treatment resistant manic bipolar patient with intracra- nial mass and pulmonary embolism history: Case

MUŞTUCU A., GÜLLÜLÜ R. A., EKER S. S.

KLINIK PSIKIYATRI DERGISI-TURKISH JOURNAL OF CLINICAL PSYCHIATRY , cilt.25, sa.4, ss.430-433, 2022 (ESCI)

5. ACUTE PSYCHOSIS FOLLOWING COVID-19 INFECTION: A CASE REPORT

GÜLLÜLÜ R. A., EKER S. S., SARANDÖL A.

PSYCHIATRIA DANUBINA , cilt.34, sa.1, ss.177-178, 2022 (SCI-Expanded)

6. Comparison of the burdens of caregivers of patient with bipolar disorder-I and schizophrenia patient

Hanci N., SARANDÖL A., Eker S. S., AKKAYA C.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY , cilt.19, sa.5, ss.451-458, 2018 (SCI-Expanded)

7. Can serum level of BDNF be used as a biomarker in distinction between the depressive episodes of bipolar disorder and recurrent major depressive disorder?

EKER S. S., Sarikavakli U., CANGÜR Ş., AKKAYA C.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY , cilt.18, sa.2, ss.108-112, 2017 (SCI-Expanded)

8. First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment

SARANDÖL A., SARANDÖL E., Acikgoz H. E., EKER S. S., AKKAYA C., DİRİCAN M.

PSYCHIATRY AND CLINICAL NEUROSCIENCES , cilt.69, sa.11, ss.699-707, 2015 (SCI-Expanded)

9. The efficacy of flupenthixol decanoate in bipolar disorder patients who have no sufficient remission with existing treatments

EKER S. S., AKKAYA C., Pirincci E., CANGÜR Ş., KIRLI S.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY , cilt.16, sa.5, ss.364-367, 2015 (SCI-Expanded)

10. Investigating the relationship between pain and major depressive disorder in terms of depressive symptoms

EKER S. S., Eker O. C., KIRLI S., ÖZKAYA G., Baykal B. E., AKKAYA C.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY , cilt.16, sa.4, ss.231-237, 2015 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

11. Relationship between Antidepressant Prescription Rates and Features of Schizophrenic Patients and Its Outcome in Schizophrenia Treatment

Hanci N., Eker O. C., Miraloglu O., Uslu M. A., ÖZKAYA G., EKER S. S.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY , cilt.52, sa.1, ss.64-68, 2015 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

12. Can BDNF and IL-2 be indicators for the diagnosis in schizophrenic patients with depressive symptoms?

EKER S. S., Yavasci E. O., CANGÜR Ş., KIRLI S., Sarandol E.

ACTA NEUROPSYCHIATRICA , cilt.26, sa.5, ss.291-297, 2014 (SCI-Expanded)

13. Prediction of Depression in Schizophrenia Can serum Levels of BDNF or EGF Help us

Yavaşçı Öztepe E., EKER S. S., SARANDÖL E., CANGÜR Ş., Kırlı S.

Journal of Psychiatry , 2014 (Hakemli Dergi)

14. Increased plasma agmatine levels in patients with schizophrenia

Uzbay T., GÖKTALAY G., Kayir H., Eker S. S., SARANDÖL A., Oral S., et al.

JOURNAL OF PSYCHIATRIC RESEARCH , cilt.47, sa.8, ss.1054-1060, 2013 (SCI-Expanded)

15. The Predictors of Remission in Major Depressive Disorder

AKKAYA C., EKER S. S., SARANDÖL A., Cangur S., KIRLI S.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY , cilt.50, sa.2, ss.122-129, 2013 (SCI-Expanded)

16. Ziprasidone and Tardive Dystonia: A Case Report and Literature Review

Turan A. B., AKKAYA C., EKER S. S., SARANDÖL A., Karli N.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY , cilt.21, sa.3, ss.242-245, 2011 (SCI-Expanded)

17. The Effects of Reboxetine and Venlafaxine on ECG Variables in Depressed Patients

EKER S. S., AKKAYA C., Cangur S., Yuvanc U., SARANDÖL A., KIRLI S.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY , cilt.21, sa.1, ss.11-17, 2011 (SCI-Expanded)

18. Early-versus late onset dysthymic disorder: clinical characteristics, symptom profile and social adaptation

EKER S. S., AKKAYA C., Cangur S., SARANDÖL A., Yavasci E. O., Sarikavakli U., et al.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY , cilt.12, sa.1, ss.49-54, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

19. Comparison of The Efficacy and Safety of Sertraline, Reboxetine, and Venlafaxine in Patients with Major Depressive Disorder: A Pooled Analysis of Four Randomized, Open-Label Trials

Akkaya C., Kirli S., EKER S. S., Cangur S., Canbazoglu M., Sarandol A.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY , cilt.20, sa.4, ss.274-287, 2010 (SCI-Expanded)

20. Behavioral Disturbances and Depression of Patients with Parkinson's Disease have Significant Impact on Caregivers' Burden and Depression

Sarandol A., EKER S. S., Sivrioglu E. Y., ÖZKAYA G., Erer S., ZARİFOĞLU M., et al.

NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH , cilt.16, ss.91-96, 2010 (SCI-Expanded, Scopus)

21. The Association of the Level of Caregiver Burden with the Sociodemographic Variables and the Characteristics of the Disorder in Schizophrenic Patients

Aydin A., EKER S. S., Cangur S., SARANDÖL A., KIRLI S.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY , cilt.46, ss.10-14, 2009 (SCI-Expanded)

22. The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases

Eker S. S., Sarandol A., Akkaya C., Sivrioglu E. Y., Kirli S.

JOURNAL OF PSYCHOPHARMACOLOGY , cilt.23, sa.8, ss.993-996, 2009 (SCI-Expanded)

23. Effects of adding depot antipsychotic medication to oral antipsychotic regimen on treatment compliance in schizophrenic patients.

EKER S. S., AKKAYA C., Cangur S., SARANDÖL A., Deniz G., KIRLI S.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY , cilt.19, sa.3, ss.273-278, 2009 (SCI-Expanded)

24. Factors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor?

Sivrioglu Y., KIRLI S., AKKAYA C., Eker S. S., ÖZKAYA G.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY , cilt.19, 2009 (SCI-Expanded)

25. Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?

EKER S. S., KIRLI S., AKKAYA C., Cangur S., SARANDÖL A.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY , cilt.10, sa.4, ss.400-408, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

26. Addiction to topically used cyclopentolate hydrochloride: A case report

AKKAYA C., Kocagoz S. Z., SARANDÖL A., EKER S. S., KIRLI S.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY , cilt.32, sa.7, ss.1752-1753, 2008 (SCI-Expanded)

27. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder

EKER S. S., AKKAYA C., SARANDÖL A., Cangur S., SARANDÖL E., KIRLI S.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY , cilt.32, sa.4, ss.955-961, 2008 (SCI-Expanded)

28. Evaluation of psychiatric disorders in Parkinson's disease Parkinson hastalarinda psikiyatrik bozukluklarin araştirilmasi

SARANDÖL A., EKER S. S., SİVRİOĞLU E. Y., ÖZKAYA G., Erer S., ZARİFOĞLU M., et al.

Yeni Symposium , cilt.45, sa.2, ss.74-79, 2007 (Scopus)

29. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems

Sarandol A., Sarandol E., Eker S. S., Erdinc S., Vatansever E., Kirli S.

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL , cilt.22, sa.2, ss.67-73, 2007 (SCI-Expanded)

30. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition

Sivrioglu E. Y., Topaloglu V. M., Sarandol A., Akkaya C., Eker S. S., Kirli S.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY , cilt.31, sa.2, ss.548-550, 2007 (SCI-Expanded)

31. Parkinson hastalarında Psikiyatrik Bozuklukların Araştırılması

SARANDÖL A., EKER S. S., SİVRİOĞLU E. Y., ÖZKAYA G., ERER ÖZBEK Ç. S., ZARİFOĞLU M., et al.

Yeni Sempozyum Dergisi , cilt.45, sa.2, ss.74-79, 2007 (Scopus)

32. A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trial

Yazicioglu B., Akkaya C., Sarandol A., Akgoz S., Eker S. S., Kirli S.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY , cilt.30, sa.7, ss.1271-1276, 2006 (SCI-Expanded)

33. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder

Sarandol A., Sarandol E., Eker S. S., Karaagac E. U., Hizli B. Z., Dirican M., et al.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY , cilt.30, sa.6, ss.1103-1108, 2006 (SCI-Expanded)

34. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study

Akkaya C., Sivrioglu E. Y., Akgoz S., Eker S. S., Kirli S.

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL , cilt.21, sa.5, ss.337-345, 2006 (SCI-Expanded)

35. Comparison of Effects of Sertraline and Reboxetine on the Loss of Social Functioning in Major Depressive Disorder: A Randomized, Open-Labeled Study

AKKAYA C., SİVRİOĞLU E. Y., SARANDÖL A., EKER S. S., KIRLI S.

DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES , cilt.19, sa.1, ss.5-13, 2006 (ESCI)

36. Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder

Eker S. S., Akkaya C., Akgoz S., Sarandol A., Kirli S.

TURK PSIKIYATRI DERGISI , cilt.16, sa.3, ss.153-163, 2005 (SSCI)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 5

1. Arilai: a naturalistic open-label study of aripiprazole long acting injectable efficacy on functioning and quality of life in schizophrenia patients

ALPTEKİN K., ANIL YAĞCIOĞLU A. E., EKER S. S., Yıldız M., Kaymak Ulusoy S., TAMAM L., et al.

32nd ECNP, Kopenhag, Danimarka, 7 - 19 Eylül 2019, (Özet Bildiri)

Kitaplar 2

1. Şİzofrenide eştanılı durumlar

EKER S. S.

ŞİZOFRENİ VE DİĞER PSİKOTİK BOZUKLUKLAR, , Editör, BAYT, ss.116-136, 2018

2. The use of Psychotropic Drugs in Renal Diseases

EKER S. S.

PSYCHOTROPIC DRUGS AND MEDICAL CONDITIONS, Faruk Uğuz, Editör, Nova Science Publishers, Inc., New York, ss.141-156, 2017

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

686

H-İndeks (WoS)

Atıf (Scopus)

772

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Atıf (Sobiad)

H-İndeks (Sobiad)

Tez Danışmanlığı

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler